A GLP-1 journey encompasses the complete treatment experience with glucagon-like peptide-1 receptor agonistsmedications FDA-approved for type 2 diabetes and chronic weight management
Tu C, Lu H, Zhou T, Zhang W, Deng L, Cao W, et al
For once-weekly injections, the pharmacokinetic effect on gastric emptying is not confined to the injection day
Frontiers in pancreatic cancer on biomarkers, microenvironment, and immunotherapy
Weight loss points toward semaglutide
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management (Mounjaro) and chronic weight management (Zepbound)